



Resource impact template

Resource impact

Published: 24 June 2026

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisals guidance for untreated multiple myeloma:

- [Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable](#) (2026) NICE technology appraisal guidance 1170
- [Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable](#) (2025) NICE technology appraisal guidance 1098
- [Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable](#) (2023) NICE technology appraisal guidance 917
- [Lenalidomide plus dexamethasone for previously untreated multiple myeloma](#) (2019) NICE technology appraisal guidance 587
- [Bortezomib and thalidomide for the first-line treatment of multiple myeloma](#) (2011) NICE technology appraisal guidance 228